TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24079716

Group type: EXPERIMENTAL
Intervention: Rotarix (RIX4414) - two doses (0, 2-month schedule)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 15
Study: 24079992

Group type: EXPERIMENTAL
Intervention: PRIME intervention (Health Centre Management, Fever Case Management, Patient-Centered Services, support for supplies of malaria diagnostics and antimalarial drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health worker training, health centre management tools, supply of artemether-lumefantrine (AL) and rapid diagnostic tests (RDTs) for malaria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing hypotheses and interpreting realities of the intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contextual record of factors affecting implementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broader impacts of the intervention and trial activities
Number of subjects: 0
Study: 24080250

Group type: EXPERIMENTAL
Intervention: Montelukast treatment
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Montelukast withdrawal
Number of subjects: 42
Study: 24080704

Group type: EXPERIMENTAL
Intervention: Subclinical diabetic macular edema (DME)
Number of subjects: 348

Group type: COMPARATOR
Intervention: No subclinical diabetic macular edema (DME)
Number of subjects: 348
Study: 24081577

Group type: EXPERIMENTAL
Intervention: Clofarabine (20 mg/m² × 5 days) plus low-dose cytarabine (20 mg/m² × 14 days)
Number of subjects: 11
Study: 24081739

Group type: EXPERIMENTAL
Intervention: Cold-induced BAT activity (CIBA) after exposure to 16°C
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CIBA after fasting (n = 6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CIBA after 24 hours of overfeeding (n = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Baseline CIBA
Number of subjects: 16
Study: 24081970

Group type: EXPERIMENTAL
Intervention: Tricuspid-valve regurgitant jet velocity ≥3.2 m/s
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: Confirmed PAH
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 1309
Study: 24081973

Group type: EXPERIMENTAL
Intervention: Anticoagulation in patients with IPAH
Number of subjects: 1283

Group type: COMPARATOR
Intervention: Anticoagulation in patients with other forms of PAH
Number of subjects: 1283
Study: 24082310

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Oxygen desaturation index (ODI)
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: Daily energy expenditure
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: AHI
Number of subjects: 833
Study: 24082655

Group type: EXPERIMENTAL
Intervention: Metabolomics + morphology group (ViaMetrics-E)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Morphology group
Number of subjects: 125
Study: 24086319

Group type: EXPERIMENTAL
Intervention: Prophylactic cotrimoxazole from 1 to 6 months
Number of subjects: 1705

Group type: COMPARATOR
Intervention: Prophylactic cotrimoxazole exposure
Number of subjects: 1705
Study: 24088092

Group type: EXPERIMENTAL
Intervention: Global cognition assessment at 3 months
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Global cognition assessment at 12 months
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Executive function assessment at 3 months
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Executive function assessment at 12 months
Number of subjects: 821
Study: 24088306

Group type: EXPERIMENTAL
Intervention: Low-risk group (SBP >115 mmHg and HR <70 beats/min)
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Middle-risk group (SBP 89-115 mmHg and HR >76 beats/min)
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: High-risk group (SBP <89 mmHg regardless of HR values)
Number of subjects: 3029
Study: 24088548

Group type: EXPERIMENTAL
Intervention: GH treatment
Number of subjects: 5805
Study: 24088719

Group type: EXPERIMENTAL
Intervention: a priori diet-quality score
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: meat dietary pattern
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: fruit-vegetable dietary pattern
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: grains (whole and refined), processed meats, beverages (coffee, meal-replacement drinks, beer, and wine)
Number of subjects: 2632

Group type: EXPERIMENTAL
Intervention: whole fruit (not juices), organ meats, fried meats and fish, soy and nondairy products
Number of subjects: 2632
Study: 24089587

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) 5 mg/kg every 6 weeks for 56 weeks, then reduced to 3 mg/kg every 8 weeks during the second year, with concomitant MTX at median dose 7.5 mg/week.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Infliximab (IFX) treatment
Number of subjects: 19
Study: 24089677

Group type: EXPERIMENTAL
Intervention: Endostatin/collagen XVIII
Number of subjects: 30
Study: 24090033

Group type: EXPERIMENTAL
Intervention: Home administration of pemetrexed maintenance therapy (500 mg/m² every 3 weeks until progressive disease or unacceptable toxicity)
Number of subjects: 50
Study: 24090077

Group type: EXPERIMENTAL
Intervention: 25 mg oral dose of DMAA
Number of subjects: 7
Study: 24090083

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention program (ILI)
Number of subjects: 199
Study: 24091564

Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation (EPNS)
Number of subjects: 106
Study: 24091623

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4541

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4541

Group type: EXPERIMENTAL
Intervention: AI/tamoxifen treatment
Number of subjects: 4541
Study: 24091982

Group type: EXPERIMENTAL
Intervention: sunitinib/XP
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: sunitinib/XELOX
Number of subjects: 76
Study: 24092248

Group type: EXPERIMENTAL
Intervention: Routine use of fractional flow reserve (FFR) during PCI
Number of subjects: 5097

Group type: COMPARATOR
Intervention: Before routine use of FFR
Number of subjects: 5097

Group type: EXPERIMENTAL
Intervention: After routine use of FFR
Number of subjects: 5097
Study: 24092875

Group type: COMPARATOR
Intervention: SCORE algorithm
Number of subjects: 2321

Group type: EXPERIMENTAL
Intervention: SCORE-HDL algorithm
Number of subjects: 2321
Study: 24092908

Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccination (Cervarix)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (non-vaccinated or older women)
Number of subjects: 1000
Study: 24092907

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 0
Study: 24092933

Group type: EXPERIMENTAL
Intervention: Azacitidine (75 mg/m² for 7 days) and Gemtuzumab ozogamicin (3 mg/m² on day 8)
Number of subjects: 142
Study: 24093428

Group type: EXPERIMENTAL
Intervention: PSA screening-like option (unlabelled preference)
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Labelled intent for screening
Number of subjects: 911
Study: 24093426

Group type: EXPERIMENTAL
Intervention: 100 μg CHP-NY-ESO-1 vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 200 μg CHP-NY-ESO-1 vaccine
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study: 24093540

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) cytokine levels prior to surgery
Number of subjects: 61
Study: 24093770

Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 26
Study: 24093936

Group type: EXPERIMENTAL
Intervention: Shape Up Somerville (SUS) intervention
Number of subjects: 0
Study: 24094497

Group type: EXPERIMENTAL
Intervention: Fucosyltransferase VI (FTVI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fucosyltransferase VII (FTVII)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mock control
Number of subjects: 0
Study: 24094947

Group type: EXPERIMENTAL
Intervention: BSID-III
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: VABS-II
Number of subjects: 49
Study: 24095149

Group type: EXPERIMENTAL
Intervention: Diabetic subjects with complications
Number of subjects: 400

Group type: COMPARATOR
Intervention: Diabetic subjects without complications
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Upper and lower body strength
Number of subjects: 400
Study: 24095247

Group type: EXPERIMENTAL
Intervention: Setipiprant capsule (2 250-mg capsules)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Setipiprant tablet (500-mg tablet)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 20
Study: 24097022

Group type: EXPERIMENTAL
Intervention: Step 1 analgesic (mainly paracetamol)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Step 2 analgesic (23% dextropropoxyphene and 40.3% tramadol/paracetamol combination)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Step 3 analgesics
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Antiepileptic medication
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: No analgesic medication
Number of subjects: 1379
Study: 24097372

Group type: EXPERIMENTAL
Intervention: Pace-capture group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Adenosine group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pace-capture group (subset)
Number of subjects: 40
Study: 24097843

Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily)
Number of subjects: 10
Study: 24098507

Group type: EXPERIMENTAL
Intervention: Netazepide (YF476) administered orally for 12 weeks
Number of subjects: 8
Study: 24099345

Group type: EXPERIMENTAL
Intervention: Thrice-weekly rifampicin-based therapy
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Low baseline CD4 cell count (<100 cells/mm3)
Number of subjects: 305
Study: 24099518

Group type: EXPERIMENTAL
Intervention: T4 immunotherapy (T4(+) T-cells) administered intratumorally at doses starting from 10^7 cells to 10^9 cells.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T4 immunotherapy (T4(+) T-cells) administered intratumorally with low- or high-dose cyclophosphamide before 10^9 T4(+) T-cells.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine/in-house assays and imaging techniques used to monitor safety, efficacy, perturbation of endogenous antitumor immunity, immunogenicity, and T-cell trafficking.
Number of subjects: 0
Study: 24099585

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (12 mg/m²)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (10 mg/m²)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (weekly administration)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (6-12 mg/m² doses)
Number of subjects: 31
Study: 24099865

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 120 mg/m² and pemetrexed 500 mg/m² intravenously every 21 days
Number of subjects: 47
Study: 24100924

Group type: EXPERIMENTAL
Intervention: Erlotinib (dose-intense)
Number of subjects: 45
Study: 24101038

Group type: EXPERIMENTAL
Intervention: R-MPV followed by rdWBRT (23.4 Gy) and consolidation cytarabine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Overall (N = 52)
Number of subjects: 52
Study: 24101373

Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg QD for 12 months
Number of subjects: 21
Study: 24101663

Group type: EXPERIMENTAL
Intervention: Dietary patterns including lesser intake of vegetables, fruits, grains, vegetable protein, glutamic acid, starch, fiber, minerals, and potassium; higher intake of processed meats, pork, eggs, and sugar-sweetened beverages; higher cholesterol and higher Na/K ratio.
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Control for higher body mass index of black women
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Control for 11 nutrient and 10 non-nutrient correlates
Number of subjects: 1559

Group type: COMPARATOR
Intervention: Control for foods/urinary metabolites
Number of subjects: 1559
Study: 24102029

Group type: EXPERIMENTAL
Intervention: Statin therapy (treated with statins)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Untreated PAD group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 24102758

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sulbactam
Number of subjects: 47
Study: 24103115

Group type: EXPERIMENTAL
Intervention: Incidence of intussusception (IS) in children < 1 year
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Incidence of intussusception (IS) in children < 2 years
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Recovery outcomes
Number of subjects: 167
Study: 24103704

Group type: EXPERIMENTAL
Intervention: Hybrid revascularisation combining off-pump left internal mammary artery grafting to the LAD through J-hemisternotomy (JOPCAB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Hybrid revascularisation combining JOPCAB with PCI
Number of subjects: 100
Study: 24105751

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 1,000 mg every 3 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 150
Study: 24105925

Group type: EXPERIMENTAL
Intervention: PHD2 silencing in hBM-MSC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHD2 inhibition with shRNAs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cotransfection with HIF-1α or VEGF-A siRNAs
Number of subjects: 0
Study: 24106115

Group type: EXPERIMENTAL
Intervention: Length of the photoreceptor cone outer segment tips (COST) line defect
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Length of the preoperative COST line defect
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Preoperative BCVA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Length of IS/OS line defect and ELM line defect
Number of subjects: 46
Study: 24106815

Group type: EXPERIMENTAL
Intervention: Active infusion of ropivacaine 0.2% at 5 mL/hr via TAP catheter
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion via TAP catheter
Number of subjects: 8
Study: 24106841

Group type: EXPERIMENTAL
Intervention: Living with Hope Program (self-administered intervention including a film and a hope activity)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Living with Hope Program
Number of subjects: 36
Study: 24106922

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with 1.8-2.0 ml of 0.75% ropivacaine plus 10 μg of fentanyl
Number of subjects: 34
Study: 24107462

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Mometasone furoate (MF)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP)
Number of subjects: 452
Study: 24108117

Group type: EXPERIMENTAL
Intervention: Severe sepsis treatment (no specific intervention details provided)
Number of subjects: 384
Study: 24108222

Group type: EXPERIMENTAL
Intervention: Autologous dermo-epidermal skin grafts (DESG) with addition of human autologous thrombin activated autologous platelet concentrate (APC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous dermo-epidermal skin grafts (DESG)
Number of subjects: 0
Study: 24108289

Group type: EXPERIMENTAL
Intervention: Anterior surgical approach
Number of subjects: 264

Group type: COMPARATOR
Intervention: Posterior surgical approach
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Both anterior and posterior approaches
Number of subjects: 264
Study: 24109169

Group type: EXPERIMENTAL
Intervention: Single-piece hydrophobic acrylic intraocular lens (enVista model MX60)
Number of subjects: 122

Group type: COMPARATOR
Intervention: FDA historical control
Number of subjects: 122
Study: 24109561

Group type: EXPERIMENTAL
Intervention: Internet-administered treatment based on guided physical exercise for Major Depressive Disorder (MDD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 48
Study: 24111225

Group type: EXPERIMENTAL
Intervention: Random forests classifier
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple linear classifier
Number of subjects: 0
Study: 24111638

Group type: EXPERIMENTAL
Intervention: Relative measurements of FEV1 decline
Number of subjects: 3218

Group type: EXPERIMENTAL
Intervention: Absolute measurements of FEV1 decline
Number of subjects: 3218
Study: 24113022

Group type: EXPERIMENTAL
Intervention: Geometric annuloplasty ring
Number of subjects: 16
Study: 24114122

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2, days 2-15
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 75 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 100 mg/m2, Capecitabine (CAP) 1600 mg/m2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 150 mg/m2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Irinotecan (IRIN) 100 mg/m2
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: All genotype groups
Number of subjects: 50
Study: 24114410

Group type: EXPERIMENTAL
Intervention: Neurology attending physicians
Number of subjects: 3124

Group type: EXPERIMENTAL
Intervention: Neurosurgery attending physicians
Number of subjects: 3124

Group type: COMPARATOR
Intervention: Surgery attending physicians
Number of subjects: 3124

Group type: EXPERIMENTAL
Intervention: All specialties
Number of subjects: 3124
Study: 24114456

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT
Number of subjects: 58
Study: 24114613

Group type: EXPERIMENTAL
Intervention: FOLFIRI-B chemotherapy
Number of subjects: 31
Study: 24114964

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 451

Group type: COMPARATOR
Intervention: Platinum-based doublet therapy (carboplatin plus paclitaxel)
Number of subjects: 451
Study: 24115141

Group type: EXPERIMENTAL
Intervention: Increased expression of TGF-β
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Increased expression of IL-4
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Increased expression of IL-13
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: IL-4 and TGF-β expression
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Higher levels of IL-13 expression
Number of subjects: 20
Study: 24117042

Group type: EXPERIMENTAL
Intervention: Fluorescent-PCR (F-PCR)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Immunophenotypic response
Number of subjects: 130
Study: 24117272

Group type: EXPERIMENTAL
Intervention: Temozolomide for patients with O6-methylguanine methyltransferase methylated tumors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (radiochemotherapy)
Number of subjects: 0
Study: 24118452

Group type: EXPERIMENTAL
Intervention: Anagrelide (starting dose 1 mg/d in 52.6% of patients; 0.5 mg/d in 41.1%)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Anagrelide initiation consistent with SPC
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Anagrelide after discontinuing previous cytoreductive therapy (CRT)
Number of subjects: 177
Study: 24118844

Group type: EXPERIMENTAL
Intervention: Collagen-coated Prolene mesh
Number of subjects: 161

Group type: COMPARATOR
Intervention: Anterior colporrhaphy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Questionnaires (Pelvic Floor Impact Questionnaire, Pelvic Floor Distress Inventory, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire)
Number of subjects: 161
Study: 24119109

Group type: EXPERIMENTAL
Intervention: ABMR score from microarray-based test
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional assessment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ABMR score
Number of subjects: 300
Study: 24119174

Group type: EXPERIMENTAL
Intervention: HEPHAISTOS unloading orthosis for 56 days
Number of subjects: 11
Study: 24119247

Group type: EXPERIMENTAL
Intervention: T. cruzi I
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Non-I
Number of subjects: 30000
Study: 24119319

Group type: EXPERIMENTAL
Intervention: Tadalafil 2.5mg
Number of subjects: 1913

Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg
Number of subjects: 1913

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1913
Study: 24119533

Group type: EXPERIMENTAL
Intervention: Educational community resource use (nutrition and physical activity classes)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Fewer depressive symptoms
Number of subjects: 207
Study: 24119589

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 15545
Study: 24119590

Group type: EXPERIMENTAL
Intervention: Insulin aspart added to existing basal insulin (n=519)
Number of subjects: 66726

Group type: EXPERIMENTAL
Intervention: Switched from biphasic insulin (n=947)
Number of subjects: 66726

Group type: EXPERIMENTAL
Intervention: Switched from NPH plus human meal-time insulins (n=586)
Number of subjects: 66726

Group type: EXPERIMENTAL
Intervention: Insulin-naïve begun with basal plus insulin aspart (n=1594)
Number of subjects: 66726
Study: 24119776

Group type: EXPERIMENTAL
Intervention: Accommodative insole
Number of subjects: 21
Study: 24120120

Group type: EXPERIMENTAL
Intervention: Vitamin D3 fortified bread (125 μg daily) for 1 year
Number of subjects: 23
Study: 24120253

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once daily for 52 weeks
Number of subjects: 3091

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3091
Study: 24120271

Group type: EXPERIMENTAL
Intervention: 12-item Chinese version of Stroke-Specific Quality of Life Scale (SSQOL-a)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 12-item Chinese version of SSQOL-a
Number of subjects: 186
Study: 24120338

Group type: EXPERIMENTAL
Intervention: Endoscopic hemostatic powder (21 g applied during endoscopy)
Number of subjects: 9
Study: 24120380

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg, 150 mg, 225 mg, and 300 mg given orally once daily for 27 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 19
Study: 24120629

Group type: EXPERIMENTAL
Intervention: Ultralow risk group (pretest probability < 2.5%)
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 840